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Abstract 
Objectives 
Lung squamous cell carcinoma (LUSC) often diagnosed as advanced with poor 
prognosis. The mechanisms of its pathogenesis and prognosis require urgent elucidation. This 
study was performed to screen potential biomarkers related to the occurrence, development 
and prognosis of LUSC to reveal unknown physiological and pathological processes. 
 
Materials and Methods 
Using bioinformatics analysis, the lung squamous cell carcinoma microarray datasets 
from the GEO and TCGA databases were analyzed to identify differentially expressed genes 
(DEGs). Furthermore, PPI and WGCNA network analysis were integrated to identify the key 
genes closely related to the process of LUSC development. In addition, survival analysis was 
performed to achieve a prognostic model that accomplished a high level of prediction 
accuracy. 
 
Results and Conclusion 
Eighty-five up-regulated and 39 down-regulated genes were identified, on which 
functional and pathway enrichment analysis was conducted. GO analysis demonstrated that 
up-regulated genes were principally enriched in epidermal development and DNA unwinding 
in DNA replication. Down-regulated genes were mainly involved in cell adhesion, signal 
transduction and positive regulation of inflammatory response. After PPI and WGCNA 
network analysis, eight genes, including AURKA, RAD51, TTK, AURKB, CCNA2, TPX2, 
KPNA2 and KIF23, have been found to play a vital role in LUSC development. The 
prognostic model contained 20 genes, 18 of which were detrimental to prognosis. The AUC 
of the established prognostic model for predicting the survival of patients at 1, 3, and 5 years 
  
 
was 0.828, 0.826 and 0.824, respectively. To conclude, this study identified a number of 
biomarkers of significant interest for additional investigation of the therapies and methods of 
prognosis of lung squamous cell carcinoma. 
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1. Introduction 
Lung cancer is among the deadliest malignancies globally and can be categorized into 
two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). 
NSCLC, accounting for approximately 85% of lung cancer cases, is principally divided into 
lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) depending on 
pathogenesis and histological morphology [1-3]. Many therapeutic methods are currently 
being used to treat lung cancer, such as surgical resection, chemotherapy, radiotherapy and 
targeted therapy. Because NSCLC is insensitive to radiotherapy and resistant to anticancer 
drugs, targeted therapy has become the most effective way to treat patients whose tumors 
cannot be surgically removed [4,5]. In recent years, targeted therapies have undergone 
considerable development, and some effective molecular targets have been identified, such as 
epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), etc. It has 
been confirmed that these targets are successful in lung adenocarcinoma, but not in lung 
squamous cell carcinoma, because the two major subtypes have different mutation profiles 
[6-8]. In order to better diagnose and treat patients with LUSC, an investigation of novel 
biomarkers is required. LUSC, which accounts for 30% of cases of NSCLC, is more common 
in middle-aged and older men and has a high rate of metastasis and recurrence [9]. NSCLC 
patients are mostly diagnosed during the advanced stage, their 5-year survival rate lower than 
that of early stage patients [4,10,11]. Thus, further study of prognostic markers is required so 
as to personalize cancer treatment. Although a number of studies have reported on LUSC-
related genes and prognostic markers, the specific molecular mechanisms in the pathogenesis 
and progression of LUSC have not been systematically evaluated, which constrains the 
potential for early diagnosis and treatment [12,13]. An in-depth understanding of the 
molecular mechanisms involved in the occurrence and development of lung cancer may 
provide a more effective strategy for early detection and subsequent clinical treatment. 
  
 
Therefore, novel promising biomarkers or potential drug treatments are urgently required. 
Genomic microarrays and high-throughput sequencing technology combined with 
bioinformatics analysis has gradually become a powerful tool for the discovery of disease 
biomarkers and related pathways. In the present study, three RNA microarray datasets from 
the GEO database were analyzed to identify differentially expressed genes (DEGs) in lung 
squamous cell carcinoma compared with normal tissues. Gene ontology (GO) and Kyoto 
Encyclopedia of Genes (KEGG) analyses were performed to identify key genes and pathways 
which possibly influence the pathogenesis of LUSC. On the other hand, RNAseq data from 
the TCGA database were also used to screen out DEGs for weighted gene co-expression 
network analysis (WGCNA) so as to obtain hub genes associated with the occurrence and 
development of LUSC. Eventually, key genes at the intersection of these two databases 
identified genes that are critical to the disease. In addition, we utilized patient clinical 
information from DEGs in the TCGA for univariate cox regression analysis, lasso regression 
analysis and multivariate cox regression analysis to identify prognostic-related key genes. 
This ensured that an improved understanding of the mechanism and prognosis of lung 
squamous cell carcinoma was obtained. 
 
2. Material and methods 
2.1 Data Collection and data processing 
The Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) database 
from the National Center for Biotechnology Information was searched for publicly available 
studies and samples that fulfilled the following criteria for analysis: (1) the gene expression 
data series contained LUSC tissue and normal tissue samples; (2) the species of the samples 
was Homo Sapiens. Finally, three gene expression profiles (GSE2088, GSE6044, GSE19188) 
were collected for further analysis [14]. These three datasets were downloaded, the details of 
  
 
which are shown in Sup.Table 1. GEO2R was used to calculate the fold change value and P-
values of every gene in each group. Any gene for which |log2FC| > 1 and P-value < 0.05 was 
defined as a differentially expressed gene [15]. If multiple probes corresponded to the same 
gene, the maximum value of fold change was considered the gene expression level. 
2.2 TCGA data validation 
To ensure accuracy, further validation analysis was performed to confirm the results. 
LUSC RNAseq data was downloaded from The Cancer Genome Atlas (TCGA, 
https://www.cancer.gov/tcga) database, acquired using the Illumina Hiseq platform. The 
dataset included 502 LUSC samples and 49 normal samples. The genomic data used was 
standardized using the fpkm method [16]. For repetitive genetic data, the largest value was 
utilized as the expression level. Genes with a mean expression of less than 0.5 were excluded 
in each case to ensure significantly expressed genes were evaluated. The p-values of 
differentially-expressed genes were identified using a Wilcox test. From analysis methods of 
the GEO data, DEGs in the SCC samples compared with normal samples were identified. 
Raw P-values obtained from the Wilcox test and log2FC calculation were adjusted using the 
BH16 method [17]. Thresholds of |log2FC| > 1.0 and an adjusted P-value of < 0.05 were 
selected. The process above was conducted using the R package "limma". 
2.3 Functional and pathway enrichment analysis 
The GO database has a large collection of gene annotation terms, allowing genome 
annotation using consistent terminology. GO enrichment analysis including molecular 
function, cellular components and biological processes, identified which GO terms were over 
or underrepresented within a given set of genes [18]. The KEGG knowledge database, an 
integrated database resource, is generally used to identify functional and metabolic pathways 
[19]. GO and KEGG analysis were both conducted using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/), analysis tools for 
  
 
extracting meaningful biological information from multiple gene and protein collections 
[20,21]. Up- and down-regulated genes were analyzed separately, a P-value < 0.05 
considered the threshold value. 
2.4 PPI network construction and analysis of modules 
Protein-protein interaction (PPI) networks can assist in identifying key genes and pivotal 
gene modules involved in the development of LUSC from an interaction level. The Search 
Tool for The Retrieval of Interaction Genes (STRING, https://string-db.org/) was used to 
construct PPI networks. STRING is a database which provides critical assessment and 
integration of protein–protein interactions, including physical and functional associations 
[22]. DEGs were mapped to STRING to evaluate the PPI information and set confidence 
score > 0.4 as the cut-off standard. Cytoscape was used to visualize the PPI network, a 
practical open-source software tool for the visual exploration of biomolecule interaction 
networks consisting of protein, gene and other types of interaction [23]. Module analysis was 
conducted using the plug-in Molecular Complex Detection (MCODE) in Cytoscape to 
display the biological significance of gene modules [24]. 
2.5 Weighted correlation network analysis of DEGs 
In the WGCNA algorithm [25], the power exponential weighting of gene correlation 
coefficients was used to represent the correlation between genes. The power value 𝛽 was 
selected such that connections between genes were subject to scale-free network distribution. 
A topological matrix that incorporated surrounding genetic information was calculated 
relative to distance d. 
𝑆𝑖𝑗   = cor(i, j) 
𝛼𝑖𝑗  = |𝑆𝑖𝑗|
𝛽
 
  
 
 
𝑑𝑖j  = 1 – 𝜔𝑖𝑗 
where 𝑙𝑖𝑗  = ∑𝑢 𝛼𝑖𝑢𝛼𝑢𝑗 and 𝑘𝑖  = ∑𝑢 𝛼𝑖𝑢  represented node connectivity. The samples were 
firstly clustered using hierarchical clustering and the threshold set to 40,000 to eliminate 
outliers. d was then calculated and the dynamic pruning method was used after determining 
values of gene module parameters (maxBlocksize=7000, deepSplit = 2, minModuleSize = 80, 
mergeCutHeight = 0.25). After obtaining these, Pearson correlation coefficients of the gene 
modules and phenotypes (cancer tissue or paracancerous tissue samples) were calculated. 
This allowed selection of gene modules closely related to tumorigenesis. Genes in the gene 
modules from GO and KEGG analysis were used to observe the function of each gene 
module. Next, two indicators for the genes in these gene modules were calculated: one was 
the Pearson correlation coefficient of the gene in the module and the first principal 
component of the module, termed Module Membership (MM); the other is the Pearson 
correlation coefficient of the gene and phenotype in the sample, termed Gene Significance 
(GS). If a gene within a module had both large MM and GS, then the gene was considered to 
be a key gene in the module. In this study, genes in which the MM and GS were in the upper 
quartile of all genes in the module were identified as key genes. The key genes in key 
modules (modules with a high correlation coefficient for phenotype) were compared with key 
genes derived from PPI to obtain decisive genes in the development of LUSC. The WGCNA 
calculations were accomplished using the "WGCNA" package in R [26].  
2.6 Survival analysis 
Patient clinical data were downloaded from the TCGA website, then samples missing 
overall survival (OS) data were deleted, finally resulting in a total of 493 samples for survival 
analysis. Univariate Cox proportional hazards regression analysis was used to screen for 
 
 
 
  
 
genes significantly associated with prognosis (P < 0.05) [27]. Later, lasso regression analysis 
was used to eliminate collinearity between genes. After performing 1000 10-fold cross-
validations, the λ value in which the error was minimized was selected as the optimum λ 
parameter value [28]. Then multivariate Cox proportional hazards regression analysis was 
used to find key genes involved in the establishment of a prognostic model [29]. The model 
used disease risk scores as predictors of prognostic status. The disease risk score was 
determined by parameter β of the multivariate Cox proportional hazards regression analysis 
and the magnitude of the expression of each gene in the sample, using the following formula: 
 
where Expi and β are the expression levels of gene i in a particular patient and coefficients of 
the gene i in the multivariate cox regression analysis [30]. The risk score for each patient was 
calculated, which were then categorized into high or low-risk in comparison with the median 
value. Kaplan-Meier survival curves were then plotted to evaluate whether the prediction 
effect of the model was significant (p<0.05). The statistical method used in this process was a 
Log-rank test. The predictive performance of this model at different endpoints (1, 3 or 5 
years) was assessed using a time- dependent receiver operating characteristic (ROC) curve 
[31]. The R packages used in the survival analysis procedure included: "survival", "caret", 
"glmnet", "survminer" and "survivalROC". 
 
3. Results 
3.1 Identification of DEGs 
Prior to GEO2R analysis, hierarchical clustering was employed to detect sample groups 
and remove data deviating from the sample group. After measuring the quality of samples, in 
total there were 97 normal lung samples and 84 with LUSC. Finally, a total of 1013, 675 and 
Risk score = ∑ 𝐸𝑥𝑝𝑖 × 𝛽𝑖 
𝑁 
i=1 
  
 
3398 DGEs were identified from the three datasets. Among these DEGs, 128 genes were 
found in all three sets, including 88 significantly up-regulated DEGs and 4 significantly 
down-regulated DEGs. In a TCGA dataset containing 49 normal samples and 499 LUSC 
samples, 3348 up-regulated genes, 3387 down-regulated genes were identified (information 
on DEGs of the three GEO and one TCGA datasets and the overlap of genes between the 
datasets is displayed in Supplementary Table). The intersection is shown in Figure 1, 
including 85 significantly up-regulated and 39 down-regulated genes, the change in direction 
of expression of TCGA consistent with the DEGs in the GEO database. These genes were 
used to perform subsequent functional and pathway enrichment analysis. 
3.2 GO term and KEGG pathway enrichment analysis of DEGs 
The function and mechanism of the DEGs identified is this way were further evaluated 
by GO term and KEGG pathway analysis. Up- and down-regulated genes were uploaded to 
DAVID to conduct the analysis. In biological processes, up-regulated DEGs were 
significantly associated with epidermis development, collagen catabolic process, collagen 
fibril organization. Down-regulated DEGs were predominantly involved in cell adhesion, 
signal transduction, positive regulation of inflammatory response and regulation of cell 
growth. For molecular function, significantly up-regulated DEGs were represented by 
response to protein binding, and structural molecular activity while significantly down-
regulated DEGs were involved in flavin adenine dinucleotide binding, thrombospondin 
receptor activity, and protein binding. For cellular components, significantly up-regulated 
DEGs were enriched in cytosol, extracellular matrix, desmosome and those that were 
significantly down-regulated were found in extracellular exosome and space, and membrane 
raft. Figure 2 presents additional details regarding GO term analysis. In addition, KEGG 
pathway analysis identified six enriched pathways, in which three were over-represented in 
up-regulated genes, including cell cycle, ECM-receptor interaction, and amoebiasis. Down-
  
 
regulated genes enriched in three metabolic pathways, namely drug metabolism of 
cytochrome P450, tyrosine metabolism and phenylalanine metabolism (Sup.Table 2). 
3.3 PPI network analysis of DEGs 
The PPI network was constructed by Cytoscape based on the STRING database, 
consisting of 105 nodes and 483 edges, including 76 up- and 29 down-regulated genes 
(Figure 3A). The 15 DGEs with the greatest degree of connectivity were selected as key 
genes of SCC. These genes were: RFC4, AURKA, MAD2L1, TPX2, CCNA2, AURKB, 
TTK, TOP2A, RAD51, CDKN3, TK1, KPNA2, KIF23, PBK and UBE2C, which may play 
an important role in SCC progression. MCODE in Cytoscape was used to perform module 
analysis. Four significant modules were identified after MCODE analysis. The most 
significant module (MCODE score = 23.217) included 24 nodes and 267 edges (Figure 3B). 
Remarkably, genes in this module were all up-regulated. Functional and pathway enrichment 
analysis of the DEGs in this module were also conducted using DAVID. GO term enrichment 
analysis demonstrated that genes in this module were principally enriched in cell division and 
mitotic nuclear division in biological processes. Cell component analysis indicated that genes 
were significantly enriched in nucleoplasm, spindle and kinetochore. Molecular functional 
analysis demonstrated that the genes were principally involved in the binding of ATP and 
protein. KEGG analysis suggested that the genes were mainly involved in cell cycle (Table 
1). The other three modules were shown in Sup. Figure 1. 
3.4 Weighted gene correlation network analysis of DEGs 
Based on the results of hierarchical clustering, we first removed two samples: 
TCGA.63.5128.01 and TCGA.92.8065.01 (Sup. Figure 2). A value of β=5 was selected as a 
soft threshold to establish a gene regulatory network (Figure 4A). After obtaining the gene 
modules using a dynamic pruning method, it was found that the correlation coefficients of the 
blue, yellow and turquoise modules were greatest, at 0.538, -0.542 and -0.870, respectively 
  
 
(Figure 4C). In addition, the first principal component of the genes in these modules and the 
Pearson correlation coefficient between the modules in terms of clustering, were calculated. 
From these results (Figure 4B), we can see that the three modules turquoise, yellow and red 
were of greatest consistency. The correlation coefficients of these three modules and 
phenotypes were negative. The GO and KEGG analysis results for the blue, yellow and 
turquoise modules are shown in Sup. Figure 3. It can be seen that the genes in the yellow 
module were more related to inflammatory and immune response processes, also a key 
module most likely to appear in the WGCNA analysis of other disease and control groups 
[32]. The blue module was more closely related to cell cycle, mitosis, chromosome structure 
changes, etc., possibly related to the excessive proliferation of cells during cancer, targeted 
by many classic anticancer drugs such as paclitaxel and vinblastine [33,34], that play 
important roles in these processes. Thus, genes in this module are important for drug 
development. The results of GO and KEGG analysis of the turquoise module were more 
complex. This principally included cell migration and adhesion, response to hormones, tissue 
development, cell-growth pathway (TGF-beta signaling pathway, etc.), and immune 
processes. Among the 20 key genes obtained by PPI, 8 genes were located in the blue module 
and belonged to key genes of the blue module (Sup.Table 3)., while the other 11 genes were 
not present among key genes of any module. 
3.5 Survival analysis 
In order to establish an effective model for predicting prognostic status, univariate Cox 
proportional hazards regression analysis was used, with Lasso regression analysis and 
multivariate Cox proportional hazards regression analysis to screen genes. In the Univariate 
Cox proportional hazards regression analysis, 111 genes with significant effects on prognosis 
(p<0.01, Supplementary Table) were identified. In lasso regression, following 10-fold cross-
validation with 1000 repeats, λ was 0.0007079 (Figure 5D), where Partial Likelihood 
  
 
Deviance was smallest. For a λ of this value, 33 of the 111 genes had coefficients that were 
not zero (Figure 5E). A total of 20 genes were obtained by the forward-backward selection 
technique in multivariate Cox proportional hazards regression analysis for to establish a 
prognostic risk score model, namely: KLK8, POPDC3, IGLL1, PLEKHA6, PTGIS, 
ANKFN1, TM4SF19, JAG1, OR2W3, RALGAPA2, RPH3AL, PCDHGA7, C10orf55, 
ACPT, MMP12, H1FOO, CT45A10, UGT2A1, a low expression of which improved 
prognosis, and LYSMD1 and ONECUT3, where improved prognosis occurred with high 
expression (Figure 6A). 
 
Risk score = (0.00943 × KLK8) + (0.01536 × POPDC3) + (0.04825 × IGLL1) + 
(−0.04272 × LYSMD1) + (0.01822 × PLEKHA6) + (0.01318 × PTGIS) + (0.14178 × 
ANKFN1) + (0.02925 × TM4SF19) + (0.00116 × JAG1) + (0.11625 × OR2W3) + 
(−0.47624 × ONECUT3) + (0.01810 × RALGAPA2) + (0.03305 × RPH3AL) + (0.06967 
× PCDHGA7) + (0.06217 × C10orf55) + (0.08721 × ACPT) + (0.00082 × MMP12) + 
(0.58094 × H1FOO) +(0.01348 × CT45A10) + (0.02889 × UGT2A1). 
 
The distribution of risk scores and groupings are shown in Figure 5A. Patient risk scores 
are ranked and patient gene expression plotted as a heatmap (Figure 5C). It can be seen from 
the heat map that gene expression levels with a negative coefficient gradually decreased as 
risk score increased. Conversely, expression levels of genes with a positive coefficient 
displayed the opposite. As risk scores increased, the number of patients that died increased 
and duration of survival gradually decreased, confirming that the risk model was realistic 
(Figure 5B). The Kaplan–Meier curves were grouped by defined risk scores. It can be seen 
that prognosis of the low-risk group was significantly better than that of the high-risk group 
(Figure 5F). By predicting survival of patients at 1, 3, and 5 years, the area under the curve 
  
 
(AUC) of the ROC curves obtained from the risk-based prediction model was 0.828, 0.826 
and 0.824 (Figure 6B). 
 
4. Discussion 
Although many relevant studies of LUSC have been performed, early diagnosis, efficacy 
of treatment and prognosis for LUSC remain poorly resolved. For diagnosis and treatment, it 
is necessary to further understand the molecular mechanisms resulting in occurrence and 
development. Due to the development of high-throughput sequencing technology, the genetic 
alterations due to disease progression can be detected, indicating gene targets for diagnosis, 
therapy and prognosis of specific diseases. 
In this study, the intergrading of GEO and TCGA data for LUSC resulted in the 
identification of 124 significantly DEGs in lung squamous cell cancer compared with normal 
samples, including 85 up-regulated DEGs and 39 that were down-regulated. GO analysis 
demonstrated that the up-regulated genes were principally involved in epidermal 
development and DNA unwinding in DNA replication, while the down-regulated genes were 
mainly enriched in cell adhesion, signal transduction and positive regulation of inflammatory 
response. KEGG analysis indicated that these differentially expressed genes were involved in 
cell cycle regulation, cancer-related pathways, ECM receptor interaction and various 
metabolic pathways. In addition, 15 genes of high significance, including RFC4, AURKA, 
MAD2L1, TPX2, CCNA2, AURKB, TTK, TOP2A, RAD51, CDKN3, TK1, KPNA2, KIF23, 
PBK and UBE2C, were identified by constructing a PPI network. Through module analysis 
we identified four significant gene modules, in which the most significant module contained 
26 nodes and 267 edges strongly associated with cell division and related activities. 
Interestingly, the genes in this module were all up-regulated and fifteen key genes of the 
highest significance were contained in this module. Through WGCNA analysis, three 
  
 
significant gene modules, in which the blue module was positively correlated with the 
development of tumors, the opposite of the others, were obtained. Key genes identified in the 
PPI network were mostly contained in the blue module, including AURKA, RAD51, TTK, 
AURKB, CCNA2, TPX2, KPNA2 and KIF23. GO analysis indicated that the blue module 
was associated with cell cycle, consistent with PPI submodule analysis. The WGCNA 
package constructed a network based on the correlation between genes, whereas the PPI 
network was based on protein networks reported in the known literature. It seems appropriate 
to combine WGCNA and PPI methods to identify key genes. Thus, these eight genes were 
selected as hub genes for the occurrence and development of LUSC. All eight are involved in 
cell cycle progression and regulate different mitotic events. A large number of studies have 
reported that abnormal expression levels were found in multiple types of human malignancy 
and have potential as anticancer therapeutic targets [35-40]. 
AURKA and AURKB are members of the aurora kinase family and both play central 
roles in regulating cell-cycle progression from G2 through to cytokinesis. AURKA is 
involved in many mitotic events, including centrosome maturation, mitosis entry, mitotic 
spindle formation and cytokinesis [41]. AURKB exerts its function by regulating 
chromosomal alignment, segregation and cytokinesis, as the catalytic protein of the 
chromosomal passenger complex (CPC) [40]. Yu et al. identified functional interaction 
between AURKA and AURKB, assisting in protection of their stability and partially 
explaining their persistent high expression and activity in cancers [43]. Ma et al. verified that 
up-regulation of miR-32 down-regulated AURKA and thus inhibited the occurrence and 
development of NSCLC [44]. Jin et al. performed a bioinformatics analysis and proposed that 
AURKB may be the key gene in LUAC and could result in poor prognosis [45]. 
RAD51 is the central protein in the homologous recombination (HR) pathway and is 
critical for DNA replication and repair. Recent studies have reported that RAD51 is also 
  
 
implicated in the suppression of innate immunity [46]. Hu et al. pointed out that RAD51 
expression was elevated by a KRAS mutation which predominantly occurred in lung 
adenocarcinomas. Furthermore, they found that the high expression of RAD51 was 
associated with poor survival in lung adenocarcinoma through analysis of data from the 
TCGA database [47]. Moreover, expression levels of RAD51 were also linked to resistance 
to chemotherapy. Takenaka et al. reported that the combined expression of RAD51 and 
another DNA repair enzyme, ERCC1 (Excision repair cross‐complementation group 1) is 
associated with resistance to platinum agents, indicating the potential role of RAD51 in 
prognosis [48]. 
Monopolar spindle1 (Mps1), also known as TTK, is a dual-specificity kinase that 
phosphorylates serine/threonine and tyrosine residues. TTK is a key mitotic checkpoint 
protein, similar to AURKA and AURKB. It functions as a critical component of the SAC 
(spindle assembly checkpoint) signaling cascade, ensuring correct chromosome segregation 
[49]. High expression of TTK in LUAC and LUSC has been revealed through analysis of 
TCGA data, where it eliminates lung cancer by augmenting apoptosis and polyploidy [50]. 
Cyclin family member CCNA2 is involved in cytoskeletal dynamics, epithelial–mesenchymal 
transition (EMT) and metastasis [51]. Chen et al. used two lung adenocarcinoma cell lines to 
verify that miR-137 can induce G1/S cell cycle arrest and dysregulate mRNA expression in 
cell cycle associated proteins, including CCNA2 [52]. 
TPX2, a microtubule-associated protein, is required for the formation of normal bipolar 
spindles and chromosome separation. Overexpression of TPX2 can induce abnormal 
centrosome amplification, leading to aneuploidy formation and malignant transformation of 
cells. It can also promote cell proliferation and participate in cell cycle and apoptosis 
regulation [53]. It is overexpressed in LUSC, which has been specifically verified [54]. 
Remarkably, TPX2 can specifically interact with AURKA to complete a series of biological 
  
 
functions including targeting of AURKA to the spindle microtubes and assembly of spindles 
of the correct length which faithfully segregate chromosomes [55]. Co-expression of TPX2 
and AURKA have been verified, depletion of either causing defects in the formation of 
spindles [35,55]. In LUSC, up-regulation of AURKA and TPX2 are correlated, a high 
correlation in tumor tissues having been established [56]. 
KPNA2 regulates the transportation of a variety of important proteins from the 
cytoplasm into the nucleus. Increasing evidence has shown that KPNA2 contributes to the 
process of gene regulation, including that of oncogenes and tumor-suppressor genes, further 
affecting biological functions, such as cell proliferation, differentiation, cell-matrix adhesion, 
colony formation and migration [57]. Wang et al. found that KPNA2 was overexpressed in 
the nuclei of tumor cells in NSCLC, through analysis of the cancer cell secretome and tissue 
transcriptome, suggesting that KPNA2 is a potential biomarker for NSCLC [58]. 
Nuclear protein KIF23 is reported to interact with the aurora kinase family to regulate 
cell division and cytokinesis [59]. A reduction in KIF23 gene expression was able to suppress 
cell proliferation [60]. A number of experimental and bioinformatics studies have pointed to 
high levels of KIF23 expression observed in the majority of metastatic lung cancer tissues, 
indicating that KIF23 plays a role in NSCLC occurrence and development [36,61-63]. 
Importantly, abnormal behavior of genes in lung cancer has been widely reported. However, 
its role and molecular mechanisms in LUSC require additional investigation. 
We have established a prognostic model that predicts patient survival. This model 
contains 20 key genes, some of which have not been reported in the literature in LUSC 
studies, including POPDC3, IGLL1, TM4SF19, RALGAPA2, RPH3AL, PCDHGA7 or 
ACPT. The present study found that KLK8 (kallikrein8) is involved in the development of a 
variety of tumors, including cervical, ovarian and breast cancer. KLK8 is expressed in 
different tissues and cells and regulated by steroid hormones [64-66]. KLK is distributed 
  
 
principally in normal tissues such as the kidneys, breast, skin, tonsil, testis, etc., but KLK8 is 
expressed less in the lungs, which may be a reason for the small coefficient (0.00943) for 
KLK8 in the risk score [67]. That study demonstrated that KLK8 is highly expressed in 
ovarian cancer and can be used as a marker for tumorigenesis. Whether KLK8 can be used as 
a biomarker for squamous cell carcinoma deserves further investigation [68]. High expression 
of LYSMD1 and ONECUT3 has a protective effect on squamous cell carcinoma. LYSMD1 
is a member of the LysM domain. The LysM domain is widely found in plants, bacteria, 
fungi and animals [69,70] and can be combined with a variety of other proteins. At present, 
few studies have reported on its role in mammalian tissues, but it can be seen from the results 
of survival analysis that high expression of LYSMD1 may have a protective effect on 
keratinized squamous cell carcinoma.  
The ONECUT transcription factor contains three members in mammalian cells, namely 
hepatocyte nuclear factor 6 (ONECUT-1), ONECUT-2 (OC-2) and ONECUT-3 (OC-3), roles 
of which overlap [71]. ONECUT participates in the biological functions of cell cycle and 
proliferation regulation, cell differentiation, organ formation, cell migration, cell adhesion 
and metabolism by regulation of gene expression [72]. Current studies on the regulation of 
cell proliferation by OC transcription factors are focusing mainly on ONECUT-1. It is worth 
noting that ONECUT-1 has a certain tissue specificity for the regulation of cell proliferation. 
For example, overexpression of ONECUT-1 in colonic adenocarcinoma cell line Caco-2 
inhibits cell cycle progression [73]. At present, there are few reports of the regulation of cell 
cycle in ONUCUT-3, but the high expression of this gene has a significant prognostic effect. 
In lung tissue, the expression of ONECUT-1 is reduced, so ONECUT-3 may regulate cell 
cycle and adhesion, but this requires further experimental verification. Related studies have 
shown that the occurrence of lung cancer and the metastasis of cancer cells can significantly 
change the patient's olfactory function, consistent with the genes we have identified. Thus, 
  
 
OR2W3 (olfactory receptor family 2 subfamily W member 3) could potentially be used as a 
tumor marker for the examination of squamous cell carcinoma [74,75]. 
H1FOO is an H1.8 linker histone. Expression levels of this gene are closely related to 
time course, but different from other H1 protein subtypes. It not only functions in oocyte-
embryo development transition, but also plays a crucial role in the genome reprogramming 
process. When the expression of the H1FOO gene in oocytes increases, the pluripotency of 
the cells also increases, indicating that H1FOO is involved in chromosome remodeling and 
gene reprogramming. This process is closely related to the occurrence of cancer, so to some 
extent, the levels of H1FOO expression reflect the degree of cancer cell proliferation [76,77]. 
Ankyrin repeats play an important role in the progression of inflammation-associated 
tumors. At present, it has been found that ankyrin repeats are highly expressed in cervical 
cancer, liver cancer, cholangiocarcinoma, breast cancer, etc. and that their expression levels 
are closely related to depth of tumor invasion, grading stage [78] and tumor metastasis. 
Studies have suggested that ankyrin repeats may play a role in cell proliferation by regulating 
the function of the important tumor suppressor genes p53, Rb and hypoxia inducible factor-1 
(HIF-1), and the IL-8 pathway [79]. The protein fibronectin is a glycoprotein secreted by 
tumor-associated fibroblasts and tumor cells. Deposition of fibronectin stimulates cancer cells 
to bind to insulin-like growth factor binding protein-3 (IGFBP-3) and epidermal growth 
factor (EGF) [80]. When fibronectin increases in concentration, IGFBP-3 and EGF promote 
cancer cell proliferation. Conversely, if fibronectin is deleted, cancer cell proliferation is 
inhibited. This is consistent with the large positive coefficient (0.14178) for the ANKFN1 
(ankyrin repeat and fibronectin type III domain containing 1) gene obtained in the present 
study. 
 
5. Conclusions 
  
 
In the present study, microarray data from the GEO database were integrated with RNA 
sequencing data from the TCGA, to identify key genes and more important hub genes. 
Finally, we identified eight hub genes associated with the pathogenesis and progression of 
LUSC. Additionally, we performed survival analysis and built a Cox proportional hazards 
model to identify prognostic biomarkers. A prognostic gene signature consisting of 20 genes 
was constructed with good performance in predicting overall survival. These results will 
serve as a reference for future research on the pathogenesis and drug treatment for LUSC. 
Nevertheless, the lack of experimental verification is a limitation of this study. The 
predictions obtained from the bioinformatics analysis can be verified by future experimental 
studies. 
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Figure captions 
Figure 1. Overview of microarray signatures. (A-D). Volcano plots of DEGs of GSE2088, 
GSE6044, GSE19188 and TCGA datasets. The red and blue points in the plot represent 
statistically significant up and down-regulated DEGs. (E). Venn diagrams of DEGs of the 
three GEO and one TCGA dataset. 
Figure 2. GO enrichment analysis of DEGs. (A) Up-regulated genes. (B) Down-regulated 
genes. The y-axis shows significantly enriched GO terms, and x-axis represents significance 
of enrichment. 
Figure 3. Protein-protein interaction network analysis of DEGs. (A) PPI network of 124 
significantly differentially expressed genes. Red: up-regulated genes; Green: significantly 
down-regulated genes; (B) The most significant module of the PPI network. Node size is 
positively related to degree of expression. 
Figure 4. WGCNA analysis of DEGs within the TCGA data. (A). Left panel: Abscissa: 
power value; ordinate: R2 value after linear regression of -log10 (k) and log10 (P (k)). k: 
connectivity of the gene nodes; P (k): probability of such a node. Horizontal line: 0.9. Right 
panel: Abscissa: power value; ordinate: mean connectivity of gene nodes. (B). 
Interrelationship between different gene modules. Colors in the heat map represent Pearson 
correlation coefficients between gene modules. Expression levels of gene modules are 
represented by the first principal component. (C). Gene modules and phenotypes quantified 
using Boolean variables (1 represents occurrence, 0 represents no occurrence) were used to 
calculate correlation coefficients, represented as a heat map. p- values are displayed in 
brackets. (D). Blue, yellow and turquoise module gene correlation scatter plots. X-axis 
represents molecule membership, i.e. Pearson correlation coefficients of gene and module 
(MM). Y-axis represents the importance of the gene for the phenotype, i.e. Pearson’s 
correlation coefficient of gene and phenotype (GS: phenotype is represented by a Boolean 
  
 
variable). In the yellow, blue, turquoise modules, the upper quartile value of MM was 0.756, 
0.683 and 0.708 respectively; the upper quartile value of GS was 0.431, 0.390 and 0.631, 
respectively. 
Figure 5. Lasso regression and multivariate cox regression related results. (A). Distribution 
of risk scores. The abscissa is arranged in order of patient risk score, with y-axis representing 
risk score, with more than 10 records plotted as 10. Patient with a score less than the median 
is plotted in green, those equal to or greater than the median in red. (B) Distribution of 
duration of survival. The abscissa is arranged in order of patient risk score and ordinate 
representing patient survival time. (C) Heat map of gene expression levels of the most 20 
significant genes. Patient risk scores increased from left to right. (D). Results of Lasso 
regression 1000 times 10-fold cross validation. λ was determined when partial likelihood 
deviance was smallest. (E). Coefficient curve. Different colored lines represent coefficient 
sizes of individual genes in different cases. The abscissa represents log (λ) and the number of 
coefficients (top) that are not zero under this penalty factor. (F). Survival curve for patients 
with different risk scores. Patients were divided into two groups according to the median 
survival curve score. Blue represents patients with a lower risk score. p- value <0.001. 
Figure 6. (A). Forest plot for multivariate cox regression. The HR value is eβ. This figure 
displays the 95% confidence interval for the HR value over the box plot with associated p-
values. An HR of less than 1 indicates that high gene expression improves prognosis, and HR 
greater than 1 the opposite. (B). ROC curves for the model representing 1, 3 and 5-year 
predictions, from left to right, respectively. The values in brackets are the areas under the 
curve. 
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Table 1. Detailed information of the GEO datasets. 
GEO Accession Platform Number of LUSC sample Number of normal sample Total 
GSE2088 GPL962 48 28 76 
GSE6044 GPL201 9 4 13 
GSE19188 GPL570 27 65 92 
In all - 84 97 181 
 
  
  
 
Table 2. KEGG pathway enrichment analysis of DEGs. 
Term Count % P-value Genes 
Up-regulated      
hsa04110: Cell cycle 7 8.2353 0.0002 MAD2L1, TTK, PRKDC, 
PTTG1, SFN, CCNA2, 
MCM6 
hsa04512:ECM-
receptor interaction 
6 7.0588 0.0004 SDC1, COL3A1, 
COL1A1, COL11A1, 
THBS2, SPP1 
hsa05146: 
Amoebiasis 
4 4.7059 0.0413 COL3A1, COL1A1, 
SERPINB3, COL11A1 
Down-regulated     
hsa00982:Drug 
metabolism- 
cytochrome P450 
5 0.0872 3.03E-05 FMO5, FMO3, MAOB, 
ADH1B, ALDH3B1 
hsa00350:Tyrosine 
metabolism 
3 0.0523 0.0041 MAOB, ADH1B, 
ALDH3B1 
hsa00360: 
Phenylalanine 
metabolism 
2 0.0349 0.0460 MAOB, ALDH3B1 
 
  
  
 
Table 3. MM and GS scores of eight significant genes. 
 AURKA CCNA2 TPX2 TTK AURKB RAD51 KIF23 KPNA2 
MM 0.732 0.699 0.69 0.738 0.7 0.74 0.8 0.776 
GS 0.469 0.445 0.398 0.412 0.43 0.475 0.5 0.461 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
  
 
 
 
Figure 2. A tree diagram of the hierarchical clustering results before the sample is removed. 
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Figure3. The bubble figure of the three gene modules KEGG pathway analysis. Top, middle 
and bottom are the results of blue, turquoise and yellow respectively. The bubble size is the 
number of genes, and the bubble color represents the magnitude of the significance. The 
abscissa is the degree of enrichment, and the ordinate is the different regulatory pathway 
items. 
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GO:0000022~mitotic spindle elongation
GO:0006086~acetyl−CoA biosynthetic process from p yruvate
GO:0006528~asparagine metabolic process
GO:0006529~asparagine biosynthetic process
GO:0007549~dosage compensation
GO:0009221~pyrimidine deoxyribonucleotide biosynthetic process
GO:0031055~chromatin remodeling at centromere
GO:0034501~protein localization to kinetochore
GO:0043570~maintenance of DNA repeat elements
GO:0051231~spindle elongation
GO:0000059~protein impor t into nucleus, docking
GO:0000080~G1 phase of mitotic cell cycle
GO:0000085~G2 phase of mitotic cell cycle
GO:0000090~mitotic anaphase
GO:0006200~ATP catabolic process
GO:0006297~nucleotide−excision repair, DNA gap filling
GO:0006422~aspar tyl−tRNA aminoacylation
GO:0006611~protein export from nucleus
GO:0006760~folic acid and der ivative metabolic process
GO:0009067~aspar tate family amino acid biosynthetic process
GO:0009133~nucleoside diphosphate biosynthetic process
GO:0009396~folic acid and der ivative biosynthetic process
GO:0031572~G2/M transition DNA damage checkpoint
GO:0031576~G2/M transition checkpoint
GO:0033205~cytokinesis dur ing cell cycle
GO:0043043~peptide biosynthetic process
GO:0043200~response to amino acid stim ulus
GO:0051225~spindle assembly
GO:0051319~G2 phase
GO:0051322~anaphase
GO:0000132~establishment of mitotic spindle or ientation
GO:0000245~spliceosome assemb ly
GO:0002204~somatic recombination of imm unoglobulin genes during immune response
GO:0002208~somatic diversification of immunoglobulins during immune response
GO:0002381~immunoglobulin production dur ing immune response
GO:0002566~somatic diversification of immune receptors via somatic mutation
GO:0006084~acetyl−CoA metabolic process
GO:0006220~pyrimidine nucleotide metabolic process
GO:0006270~DNA replication initiation
GO:0007076~mitotic chromosome condensation
GO:0007094~mitotic cell cycle spindle assemb ly checkpoint
GO:0007096~regulation of exit from mitosis
GO:0009132~nucleoside diphosphate metabolic process
GO:0009219~pyrimidine deoxyribonucleotide metabolic process
GO:0009263~deoxyribonucleotide biosynthetic process
GO:0009394~2'−deoxyribonucleotide metabolic process
GO:0010948~negative regulation of cell cycle process
GO:0010970~microtubule−based transport
GO:0016446~somatic hypermutation of immunoglobulin genes
GO:0030010~establishment of cell polar ity
GO:0031577~spindle checkpoint
GO:0045190~isotype switching
GO:0045839~negative regulation of mitosis
GO:0045841~negative regulation of mitotic metaphase/anaphase tr ansition
GO:0050000~chromosome localization
GO:0051294~establishment of spindle or ientation
GO:0051303~establishment of chromosome localization
GO:0051784~negative regulation of nuclear division
GO:0002200~somatic diversification of immune receptors
GO:0002377~immunoglobulin production
GO:0002440~production of molecular mediator of imm une response
GO:0002562~somatic diversification of immune receptors via germline recombination within a single locus
GO:0006284~base−excision repair
GO:0006298~mismatch repair
GO:0006405~RNA export from nucleus
GO:0007127~meiosis I
GO:0007163~establishment or maintenance of cell polar ity
GO:0014075~response to amine stim ulus
GO:0016444~somatic cell DNA recombination
GO:0016445~somatic diversification of immunoglobulins
GO:0016447~somatic recombination of imm unoglobulin gene segments
GO:0030071~regulation of mitotic metaphase/anaphase tr ansition
GO:0031023~microtubule organizing center organization
GO:0040001~establishment of mitotic spindle localization
GO:0051053~negative regulation of DNA metabolic process
GO:0051293~establishment of spindle localization
GO:0051297~centrosome organization
GO:0051653~spindle localization
GO:0000077~DNA damage checkpoint
GO:0000910~cytokinesis
GO:0006302~double−strand break repair
GO:0006418~tRNA aminoacylation f or protein translation
GO:0006986~response to unfolded protein
GO:0008033~tRNA processing
GO:0009108~coenzyme biosynthetic process
GO:0009262~deoxyribonucleotide metabolic process
GO:0040029~regulation of gene expression, epigenetic
GO:0043038~amino acid activ ation
GO:0043039~tRNA aminoacylation
GO:0051168~nuclear export
GO:0006119~oxidative phosphorylation
GO:0006268~DNA unwinding dur ing replication
GO:0006413~translational initiation
GO:0007052~mitotic spindle organization
GO:0007088~regulation of mitosis
GO:0009116~nucleoside metabolic process
GO:0022618~ribonucleoprotein complex assembly
GO:0030261~chromosome condensation
GO:0032392~DNA geometr ic change
GO:0032508~DNA duplex unwinding
GO:0045786~negative regulation of cell cycle
GO:0051170~nuclear import
GO:0051783~regulation of nuclear division
GO:0006334~nucleosome assembly
GO:0031570~DNA integr ity checkpoint
GO:0006364~rRNA processing
GO:0006732~coenzyme metabolic process
GO:0016072~rRNA metabolic process
GO:0017038~protein impor t
GO:0031497~chromatin assembly
GO:0033365~protein localization in organelle
GO:0034728~nucleosome organization
GO:0042770~DNA damage response , signal transduction
GO:0051640~organelle localization
GO:0051656~establishment of organelle localization
GO:0065004~protein−DNA comple x assembly
GO:0051028~mRNA transport
GO:0010608~posttranscriptional regulation of gene expression
GO:0033043~regulation of organelle organization
GO:0043623~cellular protein comple x assembly
GO:0051052~regulation of DNA metabolic process
GO:0051325~interphase
GO:0051329~interphase of mitotic cell cycle
GO:0000070~mitotic sister chromatid segregation
GO:0000819~sister chromatid segregation
GO:0006310~DNA recombination
GO:0006399~tRNA metabolic process
GO:0006403~RNA localization
GO:0007018~microtubule−based movement
GO:0007093~mitotic cell cycle checkpoint
GO:0042254~ribosome biogenesis
GO:0048015~phosphoinositide−mediated signaling
GO:0050657~nucleic acid transport
GO:0050658~RNA transport
GO:0051236~establishment of RNA localization
GO:0006261~DNA−dependent DNA replication
GO:0006333~chromatin assembly or disassembly
GO:0006913~nucleocytoplasmic transport
GO:0007126~meiosis
GO:0009165~nucleotide biosynthetic process
GO:0019932~second−messenger−mediated signaling
GO:0051169~nuclear transport
GO:0051327~M phase of meiotic cell cycle
GO:0006351~transcription, DNA−dependent
GO:0010564~regulation of cell cycle process
GO:0015931~nucleobase, nucleoside, nucleotide and nucleic acid transport
GO:0016568~chromatin modification
GO:0034404~nucleobase, nucleoside and nucleotide biosynthetic process
GO:0034654~nucleobase, nucleoside, nucleotide and nucleic acid biosynthetic process
GO:0051321~meiotic cell cycle
GO:0006605~protein targeting
GO:0031397~negative regulation of protein ubiquitination
GO:0032774~RNA biosynthetic process
GO:0034470~ncRNA processing
GO:0051352~negative regulation of ligase activity
GO:0051436~negative regulation of ubiquitin−protein ligase activity dur ing mitotic cell cycle
GO:0051444~negative regulation of ubiquitin−protein ligase activity
GO:0031398~positive regulation of protein ubiquitination
GO:0031400~negative regulation of protein modification process
GO:0051351~positive regulation of ligase activity
GO:0051437~positive regulation of ubiquitin−protein ligase activity dur ing mitotic cell cycle
GO:0051443~positive regulation of ubiquitin−protein ligase activity
GO:0000075~cell cycle checkpoint
GO:0000375~RNA splicing, via tr ansesterification reactions
GO:0000377~RNA splicing, via tr ansesterification reactions with b ulged adenosine as nucleophile
GO:0000398~nuclear mRNA splicing, via spliceosome
GO:0006091~generation of precursor metabolites and energy
GO:0006323~DNA packaging
GO:0007051~spindle organization
GO:0022613~ribonucleoprotein complex biogenesis
GO:0031145~anaphase−promoting comple x−dependent proteasomal ubiquitin−dependent protein catabolic process
GO:0031401~positive regulation of protein modification process
GO:0043086~negative regulation of catalytic activity
GO:0044271~nitrogen compound biosynthetic process
GO:0010498~proteasomal protein catabolic process
GO:0034613~cellular protein localization
GO:0043161~proteasomal ubiquitin−dependent protein catabolic process
GO:0051439~regulation of ubiquitin−protein ligase activity dur ing mitotic cell cycle
GO:0070727~cellular macromolecule localization
GO:0031396~regulation of protein ubiquitination
GO:0032269~negative regulation of cellular protein metabolic process
GO:0051248~negative regulation of protein metabolic process
GO:0051340~regulation of ligase activity
GO:0051438~regulation of ubiquitin−protein ligase activity
GO:0044092~negative regulation of molecular function
GO:0034660~ncRNA metabolic process
GO:0006325~chromatin organization
GO:0006511~ubiquitin−dependent protein catabolic process
GO:0007059~chromosome segregation
GO:0007346~regulation of mitotic cell cycle
GO:0031399~regulation of protein modification process
GO:0032270~positive regulation of cellular protein metabolic process
GO:0051247~positive regulation of protein metabolic process
GO:0006397~mRNA processing
GO:0000226~microtubule cytoskeleton organization
GO:0008380~RNA splicing
GO:0016071~mRNA metabolic process
GO:0043085~positive regulation of catalytic activity
GO:0044093~positive regulation of molecular function
GO:0008283~cell proliferation
GO:0006461~protein complex assembly
GO:0034622~cellular macromolecular comple x assembly
GO:0070271~protein complex biogenesis
GO:0006281~DNA repair
GO:0007010~cytoskeleton organization
GO:0006260~DNA replication
GO:0006412~translation
GO:0034621~cellular macromolecular comple x subunit organization
GO:0046907~intracellular transport
GO:0015031~protein transport
GO:0045184~establishment of protein localization
GO:0007017~microtubule−based process
GO:0051726~regulation of cell cycle
GO:0019941~modification−dependent protein catabolic process
GO:0032268~regulation of cellular protein metabolic process
GO:0043632~modification−dependent macromolecule catabolic process
GO:0044257~cellular protein catabolic process
GO:0051603~proteolysis involved in cellular protein catabolic process
GO:0010604~positive regulation of macromolecule metabolic process
GO:0010605~negative regulation of macromolecule metabolic process
GO:0030163~protein catabolic process
GO:0006396~RNA processing
GO:0006974~response to DNA damage stim ulus
GO:0006508~proteolysis
GO:0051276~chromosome organization
GO:0065003~macromolecular comple x assembly
GO:0044265~cellular macromolecule catabolic process
GO:0043933~macromolecular comple x subunit organization
GO:0009057~macromolecule catabolic process
GO:0033554~cellular response to stress
GO:0006259~DNA metabolic process
GO:0000087~M phase of mitotic cell cycle
GO:0000280~nuclear division
GO:0007067~mitosis
GO:0048285~organelle fission
GO:0051301~cell division
GO:0000279~M phase
GO:0000278~mitotic cell cycle
GO:0022403~cell cycle phase
GO:0022402~cell cycle process
GO:0007049~cell cycle
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GO:0001765~membrane raft formation
GO:0001868~regulation of complement activ ation, lectin pathway
GO:0001869~negative regulation of complement activ ation, lectin pathway
GO:0002384~hepatic immune response
GO:0030185~nitr ic oxide transport
GO:0043320~natural killer cell degranulation
GO:0001516~prostaglandin biosynthetic process
GO:0001909~leukocyte mediated cytotoxicity
GO:0001953~negative regulation of cell−matr ix adhesion
GO:0001960~negative regulation of cytokine−mediated signaling pathw ay
GO:0002456~T cell mediated imm unity
GO:0002675~positive regulation of acute inflammator y response
GO:0006929~substrate−bound cell migration
GO:0010712~regulation of collagen metabolic process
GO:0010713~negative regulation of collagen metabolic process
GO:0010745~negative regulation of foam cell differentiation
GO:0010812~negative regulation of cell−substr ate adhesion
GO:0010885~regulation of cholesterol stor age
GO:0010953~regulation of protein matur ation by peptide bond cleavage
GO:0010955~negative regulation of protein matur ation by peptide bond cleavage
GO:0014910~regulation of smooth m uscle cell migration
GO:0022614~membrane to membrane docking
GO:0032365~intracellular lipid transport
GO:0032673~regulation of inter leukin−4 production
GO:0033138~positive regulation of peptidyl−ser ine phosphorylation
GO:0035313~wound healing, spreading of epider mal cells
GO:0043536~positive regulation of blood vessel endothelial cell migr ation
GO:0044252~negative regulation of multicellular organismal metabolic process
GO:0045649~regulation of macrophage diff erentiation
GO:0045651~positive regulation of macrophage diff erentiation
GO:0046457~prostanoid biosynthetic process
GO:0046785~microtubule polymerization
GO:0048010~vascular endothelial growth factor receptor signaling pathway
GO:0048745~smooth muscle tissue development
GO:0051482~elevation of cytosolic calcium ion concentr ation during G−protein signaling, coupled to IP3 second messenger (phospholipase C activ ating)
GO:0051893~regulation of focal adhesion formation
GO:0051895~negative regulation of focal adhesion formation
GO:0060324~face development
GO:0060389~pathway−restricted SMAD protein phosphor ylation
GO:0060395~SMAD protein signal tr ansduction
GO:0060396~growth hormone receptor signaling pathway
GO:0060416~response to growth hormone stimulus
GO:0070102~inter leukin−6−mediated signaling pathw ay
GO:0070613~regulation of protein processing
GO:0001825~blastocyst formation
GO:0001910~regulation of leuk ocyte mediated cytotoxicity
GO:0001937~negative regulation of endothelial cell prolif eration
GO:0002548~monocyte chemotaxis
GO:0002688~regulation of leuk ocyte chemotaxis
GO:0002690~positive regulation of leukocyte chemotaxis
GO:0006471~protein amino acid ADP−r ibosylation
GO:0007041~lysosomal tr ansport
GO:0007043~cell−cell junction assemb ly
GO:0010332~response to gamma r adiation
GO:0010595~positive regulation of endothelial cell migr ation
GO:0010888~negative regulation of lipid stor age
GO:0015669~gas transport
GO:0022407~regulation of cell−cell adhesion
GO:0022409~positive regulation of cell−cell adhesion
GO:0030835~negative regulation of actin filament depolymer ization
GO:0032273~positive regulation of protein polymer ization
GO:0033135~regulation of peptidyl−ser ine phosphorylation
GO:0042516~regulation of tyrosine phosphor ylation of Stat3 protein
GO:0042517~positive regulation of tyrosine phosphor ylation of Stat3 protein
GO:0042531~positive regulation of tyrosine phosphor ylation of STAT protein
GO:0045429~positive regulation of nitr ic oxide biosynthetic process
GO:0045861~negative regulation of proteolysis
GO:0048286~lung alveolus development
GO:0050873~brown fat cell differentiation
GO:0051693~actin filament capping
GO:0000188~inactivation of MAPK activity
GO:0001933~negative regulation of protein amino acid phosphor ylation
GO:0002685~regulation of leuk ocyte migration
GO:0002687~positive regulation of leukocyte migration
GO:0002763~positive regulation of myeloid leukocyte differentiation
GO:0006691~leukotriene metabolic process
GO:0006957~complement activ ation, alternative pathway
GO:0007566~embryo implantation
GO:0010594~regulation of endothelial cell migr ation
GO:0010743~regulation of foam cell differentiation
GO:0010883~regulation of lipid stor age
GO:0019370~leukotriene biosynthetic process
GO:0030510~regulation of BMP signaling pathw ay
GO:0030834~regulation of actin filament depolymer ization
GO:0030837~negative regulation of actin filament polymer ization
GO:0031333~negative regulation of protein comple x assembly
GO:0031348~negative regulation of defense response
GO:0032231~regulation of actin filament b undle formation
GO:0032272~negative regulation of protein polymer ization
GO:0032526~response to retinoic acid
GO:0032663~regulation of inter leukin−2 production
GO:0033993~response to lipid
GO:0042509~regulation of tyrosine phosphor ylation of STAT protein
GO:0042632~cholesterol homeostasis
GO:0043449~cellular alkene metabolic process
GO:0043450~alkene biosynthetic process
GO:0045216~cell−cell junction organization
GO:0045428~regulation of nitr ic oxide biosynthetic process
GO:0045582~positive regulation of T cell diff erentiation
GO:0045621~positive regulation of lymphocyte diff erentiation
GO:0045766~positive regulation of angiogenesis
GO:0045807~positive regulation of endocytosis
GO:0046425~regulation of JAK−STAT cascade
GO:0046677~response to antibiotic
GO:0051017~actin filament b undle formation
GO:0051492~regulation of stress fiber f ormation
GO:0055092~sterol homeostasis
GO:0001824~blastocyst development
GO:0002673~regulation of acute inflammator y response
GO:0002761~regulation of myeloid leukocyte differentiation
GO:0006944~membrane fusion
GO:0008277~regulation of G−protein coupled receptor protein signaling pathw ay
GO:0008360~regulation of cell shape
GO:0015718~monocarboxylic acid transport
GO:0015918~sterol transport
GO:0016050~vesicle organization
GO:0017015~regulation of tr ansforming growth factor beta receptor signaling pathw ay
GO:0019217~regulation of fatty acid metabolic process
GO:0022406~membrane docking
GO:0030301~cholesterol tr ansport
GO:0031110~regulation of microtub ule polymerization or depolymer ization
GO:0032582~negative regulation of gene−specific tr anscription
GO:0032886~regulation of microtub ule−based process
GO:0033189~response to vitamin A
GO:0034329~cell junction assemb ly
GO:0045639~positive regulation of myeloid cell differentiation
GO:0045669~positive regulation of osteoblast differentiation
GO:0048008~platelet−der ived growth factor receptor signaling pathway
GO:0050729~positive regulation of inflammator y response
GO:0050818~regulation of coagulation
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GO:0051591~response to cAMP
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GO:0001936~regulation of endothelial cell prolif eration
GO:0002455~humoral immune response mediated by circulating immunoglobulin
GO:0006800~oxygen and reactive oxygen species metabolic process
GO:0006937~regulation of m uscle contraction
GO:0006953~acute−phase response
GO:0006958~complement activation, classical pathway
GO:0007588~excretion
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GO:0010565~regulation of cellular k etone metabolic process
GO:0030162~regulation of proteolysis
GO:0030595~leukocyte chemotaxis
GO:0030833~regulation of actin filament polymer ization
GO:0042326~negative regulation of phosphor ylation
GO:0043242~negative regulation of protein complex disassembly
GO:0043388~positive regulation of DNA binding
GO:0043392~negative regulation of DNA binding
GO:0043433~negative regulation of transcription factor activity
GO:0045088~regulation of innate imm une response
GO:0045765~regulation of angiogenesis
GO:0045936~negative regulation of phosphate metabolic process
GO:0048520~positive regulation of behavior
GO:0050920~regulation of chemotaxis
GO:0050921~positive regulation of chemotaxis
GO:0001818~negative regulation of cytokine production
GO:0002683~negative regulation of immune system process
GO:0006636~unsaturated fatty acid biosynthetic process
GO:0006643~membrane lipid metabolic process
GO:0006690~icosanoid metabolic process
GO:0007259~JAK−STAT cascade
GO:0007519~skeletal muscle tissue development
GO:0009266~response to temperature stimulus
GO:0010638~positive regulation of organelle organization
GO:0016049~cell growth
GO:0030100~regulation of endocytosis
GO:0031100~organ regeneration
GO:0032570~response to progesterone stim ulus
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Figure 4. The figure of the three gene modules GO analysis. Top, middle and bottom are the 
results of blue, turquoise and yellow respectively. The y-axis shows significantly enriched 
GO terms, and x-axis represents significance of enrichment. 
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